CC
OTLK icon

Chicago Capital’s Outlook Therapeutics OTLK Stock Holding History

Chicago Capital’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-973
Closed -$40K – 223
2019
Q2 		$40K Buy
+973
New +$45.3K ﹤0.01% 225

Other funds holding OTLK

LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RIA
Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

Chicago Capital's OTLK Position: Q3 2019 in Review

Chicago Capital sold out of Outlook Therapeutics (OTLK) in Q3 2019, closing a stake of 973 shares — an estimated $40K sold.

Chicago Capital first reported a position in OTLK in Q2 2019 and held it in 1 quarter. The position peaked at $40K in Q2 2019. 15 funds tracked by Wall St. Rank hold OTLK as of Q3 2019.

  • Chicago Capital reported no remaining Outlook Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Chicago Capital sold 973 Outlook Therapeutics shares in Q3 2019, an estimated $40K.
  • Chicago Capital first reported a position in Outlook Therapeutics in Q2 2019 and held it in 1 quarter.
  • Chicago Capital's Outlook Therapeutics position peaked at $40K in Q2 2019.
  • 15 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2019.

Based on Chicago Capital's 13F filing for Q3 2019, filed 29 Oct 2019.